Diabetes Clinical Research Currently Recruiting

New Treatment for Type 2 Diabetes

A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mellitus

You are eligible if you:

  • are aged between 18 and 75 years old
  • have had a diagnosis of Type 2 Diabetes for more than 6 months
  • have raised blood sugar levels
  • are overweight
  • are taking only a stable dose of Metformin to treat your Type 2 Diabetes (you can be taking medication to treat other medical conditions)
  • are not on insulin

More information (PDF, 76KB)

Consent Form (PDF, 350KB)


Diabetes and Kidney Function

A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of SCO-792 in Subjects with Type 2 Diabetes and Albuminuria

You are eligible if you :

  • are aged 18-75 years
  • are able to participate in a study for up to 17 weeks
  • are receiving stable treatment for your diabetes and diabetic kidney disease for the past 3 months

More information (PDF, 172KB)

Consent Form (PDF, 305KB)


Prolia compared with Alendronate in Women With Osteoporosis

Comparative Persistence With Prolia and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study

You are eligible if you:

  • are a Post Menopausal Female with Osteoporosis
  • take Prolia (Denosumab) or Alendronate (Fosamax)

More information and Consent Form (PDF, 232KB)


Diabetes treatment for heart disease 

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

You are eligible if you:
• are at least 40 years of age
• have been diagnosed with type 2 diabetes
• have an established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).

More information (PDF, 793KB)

Consent Form (PDF, 306KB)